NASDAQ:ALDX • US01438T1060
Past quarterly earnings results for ALDEYRA THERAPEUTICS INC (ALDX), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Actual vs estimated values, surprises, q2q growth and acceleration numbers for recent quarters.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q3 2025 | -0.13 | -0.25 | 47.98% | 48.00% | - | - | ||
| Q2 2025 | -0.16 | -0.25 | 35.53% | 42.86% | - | - | ||
| Q1 2025 | -0.17 | -0.29 | 40.48% | -21.43% | -816K | 100.00% | - | |
| Q4 2024 | -0.27 | -0.23 | -17.52% | -237.50% | - | - | ||
| Q3 2024 | -0.25 | -0.25 | 0.77% | -78.57% | - | - | ||
| Q2 2024 | -0.28 | -0.14 | -93.66% | -86.67% | - | - | ||
| Q1 2024 | -0.14 | -0.11 | -24.07% | 48.15% | 2.04M | -100.00% | - | |
| Q4 2023 | -0.08 | -0.14 | 44.08% | 63.64% | 1.894M | -100.00% | - | |
| Q3 2023 | -0.14 | -0.24 | 42.43% | 44.00% | - | - | ||
| Q2 2023 | -0.15 | -0.32 | 52.70% | 50.00% | - | - | ||
| Q1 2023 | -0.27 | -0.30 | 9.21% | 6.90% | - | - | ||
| Q4 2022 | -0.22 | -0.32 | 31.12% | 18.86% | - | - | ||
| Q3 2022 | -0.25 | -0.35 | 28.75% | 7.41% | - | - | ||
| Q2 2022 | -0.30 | -0.32 | 5.35% | -7.14% | - | - | ||
| Q1 2022 | -0.29 | -0.32 | 9.80% | -16.00% | - | - | ||
| Q4 2021 | -0.27 | -0.29 | 6.18% | 9.62% | - | - | ||
| Q3 2021 | -0.27 | -0.27 | -0.78% | -17.39% | - | - | ||
| Q2 2021 | -0.28 | -0.25 | -13.49% | -12.00% | - | - | ||
| Q1 2021 | -0.25 | -0.27 | 8.32% | 26.47% | - | - | ||
| Q4 2020 | -0.30 | -0.29 | -3.85% | - | - | - | ||
| Q3 2020 | -0.23 | -0.28 | 17.78% | - | - | - | ||
| Q2 2020 | -0.25 | -0.35 | 28.16% | - | - | - | ||
| Q1 2020 | -0.34 | -0.49 | 30.12% | - | - | - |
Notes
ALDEYRA THERAPEUTICS INC (ALDX) last reported earnings on 2/26/2026.
ALDEYRA THERAPEUTICS INC (ALDX) beat EPS estimates and missed revenue estimates in the most recent quarter.
In the last 4 quarters, ALDEYRA THERAPEUTICS INC (ALDX) has beaten EPS estimates in 3 out of 4 releases.